Radiopharmaceutical therapies have been a breakthrough cancer treatment for tumors resistant to cytotoxic chemotherapy and many new radiopharmaceutical agents are in active development.
Radiation oncology is playing an increasingly important role in theranostics—but building a successful program requires more than clinical interest alone.
Radiopharmaceutical therapies have been a breakthrough cancer treatment for tumors resistant to cytotoxic chemotherapy and many new radiopharmaceutical agents are in active development.
The 2026 Multidisciplinary Radiopharmaceutical Therapy Symposium is a two-day meeting featuring interactive and case-based educational sessions that focus on the evolving utilization of and advancements in radiopharmaceuticals in the treatment of cancer and other indications.
ASTRO’s AU Training Center Program provides radiation oncologists with a comprehensive, hands-on experience to meet Nuclear Regulatory Commission (NRC) and Agreement State requirements for Authorized User (AU) status in radiopharmaceutical therapy (RPT).
Radiopharmaceutical Therapy (RPT) is an emerging modality with significant potential to impact future oncological management across many disease settings.
Theranostics, a treatment paradigm pairing diagnostic molecular imaging with radiopharmaceutical therapy (RPT), is resurgent, mainly driven by the FDA approvals of 177Lu-dotatate for neuroendocrine tumors and 177Lu-PSMA-617 for prostate cancer.
Radiation dosimetry plays a critical role in the development and application of radiotherapeutic pharmaceuticals, ensuring both efficacy and safety in treatment.
Facebook
X
LinkedIn
Forward
